NCT03121352View on ClinicalTrials.gov

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

February 20, 2022

Study Completion Date

May 23, 2022

Conditions
Metastatic Triple Negative Breast Cancer
Interventions
DRUG

Carboplatin

AUC 4.5 IV day 1 of 21-day cycle

DRUG

Nab-paclitaxel

75mg/m2 IV days 1, 8 and 15 of 21-day cycle

DRUG

Pembrolizumab

200 mg IV every 21 days

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT03121352 - Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter